mebeverine has been researched along with Diabetes Mellitus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kozuka, C; Masuzaki, H; Okamoto, S; Shimabukuro, M; Tanaka, H; Yonamine, M | 1 |
| Abe, K; Egashira, K; Fukuda, K; Kamei, A; Kinjo, A; Kondo, T; Kozuka, C; Masuzaki, H; Morinaga, H; Nakano, K; Shimizu-Okabe, C; Takayama, C; Yasuoka, A | 1 |
1 review(s) available for mebeverine and Diabetes Mellitus
| Article | Year |
|---|---|
Brown rice-specific γ-oryzanol as a promising prophylactic avenue to protect against diabetes mellitus and obesity in humans.
Topics: Animals; Diabetes Mellitus; Diet, High-Fat; Endoplasmic Reticulum Stress; Humans; Hypothalamus; Islets of Langerhans; Obesity; Oryza; Phenylpropionates; Reward | 2019 |
1 other study(ies) available for mebeverine and Diabetes Mellitus
| Article | Year |
|---|---|
Marked augmentation of PLGA nanoparticle-induced metabolically beneficial impact of γ-oryzanol on fuel dyshomeostasis in genetically obese-diabetic ob/ob mice.
Topics: Administration, Oral; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Drug Compounding; Endoplasmic Reticulum Stress; Energy Metabolism; Food Preferences; Gastrointestinal Microbiome; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intestinal Absorption; Islets of Langerhans; Lactic Acid; Lipids; Liver; Male; Mice, Obese; Nanomedicine; Nanoparticles; Obesity; Phenylpropionates; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Technology, Pharmaceutical; Time Factors | 2017 |